Logo image of RVLP

RVL PHARMACEUTICALS PLC (RVLP) Stock Fundamental Analysis

NASDAQ:RVLP - Nasdaq - IE00BF2HDL56 - Common Stock - Currency: USD

0.0282  -0.01 (-32.05%)

After market: 0.0223 -0.01 (-20.92%)

Fundamental Rating

2

RVLP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. RVLP has a bad profitability rating. Also its financial health evaluation is rather negative. RVLP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RVLP has reported negative net income.
RVLP had a negative operating cash flow in the past year.
In the past 5 years RVLP always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: RVLP reported negative operating cash flow in multiple years.
RVLP Yearly Net Income VS EBIT VS OCF VS FCFRVLP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -100M -200M

1.2 Ratios

RVLP's Return On Assets of -79.93% is on the low side compared to the rest of the industry. RVLP is outperformed by 74.88% of its industry peers.
RVLP has a worse Return On Equity (-418.14%) than 80.68% of its industry peers.
Industry RankSector Rank
ROA -79.93%
ROE -418.14%
ROIC N/A
ROA(3y)-35.52%
ROA(5y)-35.76%
ROE(3y)-90.19%
ROE(5y)-107.06%
ROIC(3y)N/A
ROIC(5y)N/A
RVLP Yearly ROA, ROE, ROICRVLP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 74.73%, RVLP belongs to the top of the industry, outperforming 81.64% of the companies in the same industry.
RVLP's Gross Margin has improved in the last couple of years.
RVLP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y10.54%
RVLP Yearly Profit, Operating, Gross MarginsRVLP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

1

2. Health

2.1 Basic Checks

RVLP does not have a ROIC to compare to the WACC, probably because it is not profitable.
RVLP has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, RVLP has a worse debt to assets ratio.
RVLP Yearly Shares OutstandingRVLP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
RVLP Yearly Total Debt VS Total AssetsRVLP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

RVLP has an Altman-Z score of -11.70. This is a bad value and indicates that RVLP is not financially healthy and even has some risk of bankruptcy.
RVLP's Altman-Z score of -11.70 is on the low side compared to the rest of the industry. RVLP is outperformed by 80.68% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that RVLP is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, RVLP perfoms like the industry average, outperforming 59.90% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.7
ROIC/WACCN/A
WACC8%
RVLP Yearly LT Debt VS Equity VS FCFRVLP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 0.38 indicates that RVLP may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.38, RVLP is doing worse than 94.20% of the companies in the same industry.
A Quick Ratio of 0.36 indicates that RVLP may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.36, RVLP is doing worse than 93.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.36
RVLP Yearly Current Assets VS Current LiabilitesRVLP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.84% over the past year.
RVLP shows a small growth in Revenue. In the last year, the Revenue has grown by 5.64%.
The Revenue for RVLP have been decreasing by -27.35% on average. This is quite bad
EPS 1Y (TTM)27.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.43%
Revenue 1Y (TTM)5.64%
Revenue growth 3Y-40.83%
Revenue growth 5Y-27.35%
Sales Q2Q%-2.25%

3.2 Future

RVLP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.87% yearly.
The Revenue is expected to grow by 34.00% on average over the next years. This is a very strong growth
EPS Next Y27.9%
EPS Next 2Y25.51%
EPS Next 3Y20.95%
EPS Next 5Y25.87%
Revenue Next Year-28.9%
Revenue Next 2Y1.31%
Revenue Next 3Y13%
Revenue Next 5Y34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RVLP Yearly Revenue VS EstimatesRVLP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
RVLP Yearly EPS VS EstimatesRVLP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RVLP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RVLP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVLP Price Earnings VS Forward Price EarningsRVLP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVLP Per share dataRVLP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

RVLP's earnings are expected to grow with 20.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.51%
EPS Next 3Y20.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RVLP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RVL PHARMACEUTICALS PLC

NASDAQ:RVLP (10/20/2023, 8:09:06 PM)

After market: 0.0223 -0.01 (-20.92%)

0.0282

-0.01 (-32.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2023-08-14/bmo
Earnings (Next)11-08 2023-11-08/bmo
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.54%
Ins Owner Change0%
Market Cap3.14M
Analysts82.22
Price Target3.21 (11282.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-54.08%
Min EPS beat(2)-108.96%
Max EPS beat(2)0.8%
EPS beat(4)2
Avg EPS beat(4)-29.3%
Min EPS beat(4)-108.96%
Max EPS beat(4)1.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.02%
Min Revenue beat(2)-23.76%
Max Revenue beat(2)-8.29%
Revenue beat(4)0
Avg Revenue beat(4)-14.9%
Min Revenue beat(4)-23.76%
Max Revenue beat(4)-3.83%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.81%
PT rev (3m)-1.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.04%
EPS NY rev (1m)2.76%
EPS NY rev (3m)-30.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-51.29%
Revenue NY rev (1m)5.95%
Revenue NY rev (3m)-23.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.33
BVpS0.15
TBVpS-0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -79.93%
ROE -418.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.73%
FCFM N/A
ROA(3y)-35.52%
ROA(5y)-35.76%
ROE(3y)-90.19%
ROE(5y)-107.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y10.54%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 804.97%
Cap/Sales 8.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.36
Altman-Z -11.7
F-Score3
WACC8%
ROIC/WACCN/A
Cap/Depr(3y)79.08%
Cap/Depr(5y)49.88%
Cap/Sales(3y)4.49%
Cap/Sales(5y)3.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.43%
EPS Next Y27.9%
EPS Next 2Y25.51%
EPS Next 3Y20.95%
EPS Next 5Y25.87%
Revenue 1Y (TTM)5.64%
Revenue growth 3Y-40.83%
Revenue growth 5Y-27.35%
Sales Q2Q%-2.25%
Revenue Next Year-28.9%
Revenue Next 2Y1.31%
Revenue Next 3Y13%
Revenue Next 5Y34%
EBIT growth 1Y36.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.55%
EBIT Next 3Y33.43%
EBIT Next 5Y26.37%
FCF growth 1Y31.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.92%
OCF growth 3YN/A
OCF growth 5YN/A